Fintel on MSN18h
Leerink Partners Downgrades Lexicon Pharmaceuticals (LXRX)
Fintel reports that on March 4, 2025, Leerink Partners downgraded their outlook for Lexicon Pharmaceuticals (NasdaqGS:LXRX) ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...
Zacks Investment Research on MSN14h
Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates
Editas Medicine (EDIT) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.23 per share a year ago. These figures are ...
BioWorld17h
Chimerix brings a rare cancer drug to the $935M Jazz party
Jazz Pharmaceuticals plc is buying Chimerix Inc. for $8.55 a share, bringing the deal in at about $935 million. Jazz expands its cancer pipeline with the new acquisition’s lead candidate, dordaviprone ...